Chimeric Flavivirus Lyssavirus Vaccines

Patent metadata

Field	Value
Publication number	US-2025099568-A1
Application number	US-202418777908-A
Country	US
Kind code	A1
Filing date	Jul 19, 2024
Priority date	Sep 7, 2018
Publication date	Mar 27, 2025
Grant date	—

Abstract

The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region.FIG. 1A.

First claim

1 - 30 . (canceled)

31 . A method of vaccinating an individual, the method comprising:
administering a polynucleotide comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Lyssavirus G protein sequence is located at the intergenic region between an E gene and an NS1 gene of the Flavivirus, such that a chimeric virus is expressed, wherein the encoded sequence is located C terminally of an E protein of the Flavivirus and N terminally of a signal peptide of an NS1 protein of the Flavivirus, and wherein the encoded sequence comprises in the following order:
(1) a further signal peptide of a Flavivirus NS1 protein,
(2) a lyssavirus G protein lacking a functional signal peptide, comprising an IIb epitope, comprising a C terminal™ sequence, and comprising a C terminal cytoplasmatic sequence, and
(3) a TM2 domain of a flaviviral E protein.

32 . The method according to claim 31 , wherein the sequence of the live, infectious, attenuated Flavivirus is Yellow Fever virus.

33 . The method according to claim 31 , wherein the Lyssavirus is Rabies virus.

34 . The method according to claim 31 , wherein the Lyssavirus G protein is an ERA strain Rabies G protein.

35 . The method according to claim 31 , wherein the signal peptide of the NS1 protein comprises SEQ ID NO:6.

36 . The method according to claim 31 , wherein the IIb epitope comprises SEQ ID NO:15.

37 . The method according to claim 31 , wherein the TM2 domain of the flaviviral E protein is from West Nile virus.

38 . The method according to claim 31 , wherein the TM2 domain of the flaviviral E protein has SEQ ID NO:13.

39 . The method according to claim 34 , wherein the signal peptide of the Rabies G protein comprises a F14S mutation that renders the signal peptide non-functional.

40 . The method according to claim 34 , wherein the Rabies G protein lacks the N terminal signal sequence consisting of SEQ ID NO:18.

41 . The method according to claim 33 , wherein, at the junction of Flavivirus E gene, NS1 signal peptide, and Rabies G protein, the sequence of the chimeric virus comprises SEQ ID NO:21.

42 . The method according to claim 37 , wherein the live, infectious, attenuated Flavivirus is Yellow Fever virus and wherein at the junction of the West Nile virus TM2 domain and the NS1 signal sequence of the Yellow Fever virus, the sequence of the chimeric virus comprises SEQ ID NO:22.

43 . The method according to claim 31 , wherein the encoded sequence of the chimeric virus comprises SEQ ID NO:2 or a sequence having at least 95% sequence identity therewith.

44 . The method according to claim 31 , wherein the polynucleotide comprises SEQ ID NO:1 or a sequence having at least 95% sequence identity therewith.

45 . A method for inducing an immune response against a lyssavirus in an individual, the method comprising:
Administering to the individual a polynucleotide comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Lyssavirus G protein sequence is located at the intergenic region between an E gene and an NS1 gene of the Flavivirus, such that a chimeric virus is expressed, wherein the encoded sequence is located C terminally of an E protein of the Flavivirus and N terminally of a signal peptide of an NS1 protein of the Flavivirus, and wherein the encoded sequence comprises in the following order:
(1) a further signal peptide of a Flavivirus NS1 protein,
(2) a lyssavirus G protein lacking a functional signal peptide, comprising an IIb epitope, comprising a C terminal™ sequence, and comprising a C terminal cytoplasmatic sequence, and
(3) a TM2 domain of a flaviviral E protein.

46 . The method according to claim 45 , wherein the sequence of the live, infectious, attenuated Flavivirus is Yellow Fever virus.

47 . The method according to claim 45 , wherein the Lyssavirus is Rabies virus.

48 . The method according to claim 45 , wherein the Lyssavirus G protein is an ERA strain Rabies G protein.

49 . The method according to claim 45 , wherein the signal peptide of the NS1 protein comprises SEQ ID NO:6.

50 . The method according to claim 45 , wherein the IIb epitope comprises SEQ ID NO:15.

51 . The method according to claim 45 , wherein the TM2 domain of the flaviviral E protein is from West Nile virus.

52 . The method according to claim 45 , wherein the TM2 domain of the flaviviral E protein has SEQ ID NO:13.

53 . The method according to claim 48 , wherein the signal peptide of the Rabies G protein comprises a F14S mutation that renders the signal peptide non-functional.

54 . The method according to claim 48 , wherein the Rabies G protein lacks the N terminal signal sequence consisting of SEQ ID NO:18.

55 . The method according to claim 47 , wherein, at the junction of Flavivirus E gene, NS1 signal peptide, and Rabies G protein, the sequence of the chimeric virus comprises SEQ ID NO:21.

56 . The method according to claim 51 , wherein the live, infectious, attenuated Flavivirus is Yellow Fever virus and wherein at the junction of the West Nile virus TM2 domain and the NS1 signal sequence of the Yellow Fever virus, the sequence of the chimeric virus comprises SEQ ID NO:22.

57 . The method according to claim 45 , wherein the encoded sequence of the chimeric virus comprises SEQ ID NO:2 or a sequence having at least 95% sequence identity therewith.

58 . The method according to claim 45 , wherein the polynucleotide comprises SEQ ID NO:1 or a sequence having at least 95% sequence identity therewith.

Assignees

• Univ Leuven Kath

Inventors

• Dallmeier Kai
• Mishra Niraj
• Neyts Johan
• Senchez Lorena

Classifications

• C12N2820/002

  inducible or controllable · CPC title

• C12N2800/204

  of bacterial origin, e.g. BAC · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/20134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N15/85

  for animal cells · CPC title